Baird analyst Brian Skorney maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Outperform and raises the price target from $3 to $5.
Baird Maintains Outperform on Eiger BioPharmaceuticals, Raises Price Target to $5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.